Bloomage Biotechnology Corp Ltd
SSE:688363
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (53.8), the stock would be worth ¥8.39 (80% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 273.2 | ¥42.63 |
0%
|
| 3-Year Average | 53.8 | ¥8.39 |
-80%
|
| 5-Year Average | 64.4 | ¥10.06 |
-76%
|
| Industry Average | 36.8 | ¥5.74 |
-87%
|
| Country Average | 28.9 | ¥4.51 |
-89%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
¥22.4B
|
/ |
Oct 2025
¥72.5m
|
= |
|
|
¥22.4B
|
/ |
Dec 2025
¥473.9m
|
= |
|
|
¥22.4B
|
/ |
Dec 2026
¥626.4m
|
= |
|
|
¥22.4B
|
/ |
Dec 2027
¥745.1m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Bloomage Biotechnology Corp Ltd
SSE:688363
|
20.4B CNY | 273.2 | 315.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.6B USD | 20 | 86.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD | 14 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.4B USD | 15 | 19.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.9B USD | 22 | 28.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79B USD | 14.8 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.5B EUR | 42.3 | 38.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 13.1 | 30.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.6 |
| Median | 28.9 |
| 70th Percentile | 52.9 |
| Max | 49 021 |
Other Multiples
Bloomage Biotechnology Corp Ltd
Glance View
Nestled in the bustling corridors of the biotechnology industry, Bloomage Biotechnology Corp Ltd. has carved a niche as a leading player specializing in the production and innovation of biopolymers, with a particular emphasis on hyaluronic acid. Since its inception, the company has embraced a scientific approach combined with a robust business strategy, propelling it to the forefront of biotechnological advancements. Its operations are underpinned by a relentless pursuit of research and development, utilizing cutting-edge fermentation technology to manufacture high-quality hyaluronic acid that serves various industries such as cosmetics, food, and pharmaceuticals. Bloomage’s revenue model is intricately linked to the diverse applications of hyaluronic acid. By supplying raw materials to cosmetic giants, the company significantly taps into the lucrative beauty industry, as this compound is highly valued for its skin hydration properties. Additionally, Bloomage is involved in the healthcare segment, where it provides key ingredients for medical products that enhance joint health and accelerate wound healing. Through strategic partnerships and a focus on high-margin products, Bloomage not only diversifies its revenue streams but also sustains its position in competitive markets. This deliberate orchestration of science and commerce ensures the company remains at the vanguard of both innovation and profitability.
